ERBB2 and breast carcinoma: So far, PHD2-expression status and its influence on breast cancer disease was not found to correlate with either estrogen receptor (ER), progesterone receptor (PR), EGF receptor 2 HER2/neu (ERBB2) [13, 15] or p53, Ki67 and BCL2 [14].